Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Arvinas shares plunged 45% after its Pfizer-partnered breast cancer drug, vepdegestrant, failed to delay cancer progression for all patients. The drug only met its goal for a subset of patients with a ...

Mixed clinical results led shares of Arvinas Inc. (NASDAQ:ARVN) to close March 11 at $8.30, down $9.26, or 52%, after the ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...